Axsome Therapeutics is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $86.59 – a decrease of 3.4% over the previous week. Axsome Therapeutics employs 589 staff and has a trailing 12-month revenue of around $291.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $86.59 |
|---|---|
| 52-week range | $55.02 - $98.40 |
| 50-day moving average | $88.71 |
| 200-day moving average | $81.48 |
| Wall St. target price | $123.69 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.58 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $86.59 from 2024-10-04
| 1 week (2024-09-27) | -3.40% |
|---|---|
| 1 month (2024-09-06) | -7.08% |
| 3 months (2024-07-05) | 5.57% |
| 6 months (2024-04-05) | 19.85% |
| 1 year (2023-10-06) | 26.22% |
|---|---|
| 2 years (2022-10-06) | 78.54% |
| 3 years (2021-10-02) | N/A |
| 5 years (2019-10-04) | 369.07% |
| Revenue TTM | $291.5 million |
|---|---|
| Gross profit TTM | $45.9 million |
| Return on assets TTM | -28.23% |
| Return on equity TTM | -161.69% |
| Profit margin | -105.85% |
| Book value | $2.15 |
| Market Capitalization | $4.3 billion |
TTM: trailing 12 months
We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $55.02 up to $98.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 1.255. This would suggest that Axsome Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Axsome Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Check out the best-performing ETFs so far in 2024.